resq-med
Alma by ResQ Medical
Every life matters.
Every minute counts.
ResQ Medical has completed a feasibility study with no device-related adverse events. The pivotal study is now enrolling, and commercial preparation is underway.
- Feasibility complete
- Pivotal enrolling
- Commercial preparation
Our Mission
Empowering every delivery room with Alma, the next-generation low-vacuum uterine device that lets medical teams stop postpartum hemorrhage fast, with confidence and control. So every mother can return to her baby and family safely, with minimal disruption.
The Need: Addressing Postpartum Hemorrhage
After childbirth, some mothers experience postpartum hemorrhage — severe, uncontrolled bleeding usually caused by uterine atony (when the uterus fails to contract properly after delivery). If not managed quickly, this excessive bleeding can lead to serious complications, the need for blood transfusions, or even become life-threatening, separating a mother from her newborn during those critical first moments.
When standard medications and initial measures are not sufficient to control the bleeding, medical teams often use specialized intrauterine devices, such as balloon tamponade systems. These devices help stop the bleeding quickly while avoiding more invasive surgical procedures.
The Current Standard:
Uterine Balloon
Tamponade (UBT)
Traditionally, the standard of care has been the UBT: a balloon placed inside the uterus and inflated to press outward against bleeding vessels.
The Limitation:
- UBT relies on outward hydrostatic pressure. This means it actively works against the uterus’s natural need to contract inward, the body’s primary physiological mechanism for stopping bleeding.
- Be challenging to position and maintain correctly.
- Experience diminished effectiveness as the uterus attempts to push them out.
- Present variable success rates depending on the severity of the atony.
The Current Standard: Uterine Balloon Tamponade (UBT)
Traditionally, the standard of care has been the UBT: a balloon placed inside the uterus and inflated to press outward against bleeding vessels.
The Limitation:
- UBT relies on outward hydrostatic pressure. This means it actively works against the uterus’s natural need to contract inward, the body’s primary physiological mechanism for stopping bleeding.
- Be challenging to position and maintain correctly.
- Experience diminished effectiveness as the uterus attempts to push them out.
- Present variable success rates depending on the severity of the atony.
The Evolution: Working With the Body, Not Against It
The field of maternal health is moving toward low-vacuum technology, a physiologically aligned approach for managing postpartum hemorrhage caused by uterine atony. Instead of applying outward pressure, this technology uses controlled negative pressure to collapse the uterine cavity. By bringing the uterine walls together, it helps the uterus contract naturally and compresses the bleeding vessels, thereby controlling the hemorrhage quickly, effectively, and safely.
Designed for optimized performance, superior ultrasound visualization, intuitive placement, and reliable anti-clogging operation, this next-generation solution represents a significant advancement in abnormal bleeding management.
That device is Alma.
Alma
Alma is the only multi-layer low-vacuum uterine device designed to stop postpartum hemorrhage quickly and reliably
- Works with the uterus’s natural contractions (instead of fighting them) to control bleeding
- Continuously removes blood using standard wall suction already available in every delivery room
- One-handed insertion — no special orientation required
- Uses a familiar placement technique, so your team needs almost no extra training
- Early clinical data indicates bleeding is typically controlled within minutes
Simple. Fast. Reliable.
That’s why Alma is built to become the new first-line device in every delivery room.
Alma operation step by step
Advantage
Alma advances the low-vacuum category with a multi-layer anti-clogging design that supports the uterus's natural contraction. Unlike balloon-based devices that work against the body, and unlike first-generation low-vacuum systems susceptible to clogging, Alma is engineered for easier insertion, reliable performance, and efficient bleeding control.
Multi-Layer Vacuum Performance
- Anti-clogging multi-layer design
- Continuous low-level vacuum supports controlled uterine contraction
Safe and Physiological
- Semi-flexible anatomical design works with the uterus, not against it
Simple, Emergency-Ready Operation
- Enables one-handed insertion, no orientation required
- Integrates seamlessly into existing workflows, minimal training required
- Uses standard delivery-room wall suction
- Cost-effective
The Team
Tal Youdim
Founder, Chairman, VP R&D
Yael Corcos:
VP Clinical
Dr. Itamar Dach:
Founder & CEO, D.V.M.
Efrat Herscovith:
CFO, MBA, FINANCE
Alma operation meet the team
SAB
PROF. Michael Stark, Medical leader
Experience: Department Chair with a demonstrated history of working in the hospital & health care industry. Skilled in Epidemiology, Oncology, Healthcare Management, Healthcare, and Clinical Research. Strong healthcare services professional with a Master of Science (MSc) focused in Clinical Research and Biostatistics from Albert Einstein College of Medicine.
Linkedin
DR. Roy Z. Mansano Medical leader
Double board certified in Obstetrician/Gynecologist and Maternal-Fetal Medicine Perinatology. Owner of the Comprehensive Maternal Fetal Medicine Center which provides care for patients throughout Los Angeles and Ventura counties with affiliations of 7 large medical centers including Tarzana Providence Cedar Sinai Medical Center, Olive-View UCLA, Medical Center and Los Robles Medical Center where he is the perinatal director. He received his medical degree from Technion-Israel Inst of Technology Faculty of Medicine and has been in practice for more than 20 years.
Linkedin
DR. Scott G. Chudnoff, MD Medical advisor
Experience: Department Chair with a demonstrated history of working in the hospital & health care industry. Skilled in Epidemiology, Oncology, Healthcare Management, Healthcare, and Clinical Research. Strong healthcare services professional with a Master of Science (MSc) focused in Clinical Research and Biostatistics from Albert Einstein College of Medicine.
Linkedin
OR. SUSAN ALPERT Ph.D., M.D.: Regulatory strategy
Dr. Susan Alpert is a leading regulatory expert and consultant with deep experience in medical technology. She formerly served as Senior Vice President and Chief Regulatory Officer at Medtronic and spent six years as the Director of the FDA’s Office of Device Evaluation. A pediatrician and microbiologist by training, she now provides strategic guidance to help companies navigate global market authorizations.
Linkedin
BOD
DR. Ali Mafra, M.D. Board member, Medical Advisor, Co- founder
Board-certified OB/GYN and Hebrew University graduate with a career defined by clinical leadership and medical innovation. Currently serving as the Director of the Ultrasound Unit at the Scottish Hospital, I combine high-level diagnostics with a commitment to mentoring the next generation of medical professionals. As a startup founder and clinical consultant, I specialize in developing revolutionary solutions for postpartum hemorrhage and advising health-tech companies on bringing impactful women’s health products to market.
Linkedin
Shuki Porath Board member
Shuki Porath is a senior medical device executive and engineer, bringing over 20 years of experience in product management, business development, and global commercialization. His career includes leadership roles as CEO of Valcare Medical and Keystone Heart, along with a decade at Biosense Webster.
Linkedin
Hanan Herscovitch Board member
A senior financial executive currently serving as Senior Vice President and Group Controller at Novocure, with extensive experience in the medical technology and consulting sectors. His background includes roles as CFO at CogniFit and Mazor Surgical Technologies, CEO of Adi Consulting Ltd., and senior positions at Ernst & Young Israel.
Linkedin
PROF. Moussa Youdim Board member
A world-renowned expert in pharmacology, Prof. Youdim is the inventor and developer of the innovative Parkinson’s disease drug “Azilect”, Teva’s second largest innovative blockbuster, with annual revenues on $700M, and Selegiline, an MAO-B inhibitor for Parkinson’s disease treatment. Prof. Youdim has extensive experience in the pharmaceutical industry, professor emeritus at the Technion, where he was the head of the Department of Pharmacology at the Faculty of Medicine for over 30 years and was awarded the Israel Prize in 2022 for “his pioneering, groundbreaking scientific achievements in the field of neuropharmacology
Linkedin
Partner With ResQ Medical
We are actively seeking strategic partners to accelerate Alma’s path to every delivery room worldwide.
We’re looking for:
- Strategic partnerships with leading women’s-health and labor & delivery companies
- Distributors and commercial partners ready to bring Alma to hospitals and clinics
- Investment partners to support our pivotal clinical study and commercial launch
Why partner with ResQ Medical?
- Join the next-generation solution in a $1B+ postpartum hemorrhage market
- Be part of a device that works with the body, not against it
- Gain early access to a simple, next gen high-performance device designed for rapid adoption
New Northern Industrial Park, 1 Ha-Tsmikha St., Stern Building, Fl-4. Yokneam 2069207, Israel.
© 2026 ResQ Med. All Rights Reserved.